|
1
|
Understanding RAGE, the receptor for advanced glycation end products.
|
J Mol Med (Berl)
|
2005
|
4.96
|
|
2
|
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.
|
Circulation
|
2002
|
3.93
|
|
3
|
A mechanism converting psychosocial stress into mononuclear cell activation.
|
Proc Natl Acad Sci U S A
|
2003
|
3.82
|
|
4
|
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products.
|
Circ Res
|
2008
|
1.94
|
|
5
|
The RAGE axis in early diabetic retinopathy.
|
Invest Ophthalmol Vis Sci
|
2005
|
1.55
|
|
6
|
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways.
|
FASEB J
|
2004
|
1.35
|
|
7
|
Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs.
|
Diabetes
|
2003
|
1.19
|
|
8
|
Posttranslationally modified proteins as mediators of sustained intestinal inflammation.
|
Am J Pathol
|
2006
|
1.13
|
|
9
|
Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders.
|
Arch Biochem Biophys
|
2003
|
1.12
|
|
10
|
RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
|
Arterioscler Thromb Vasc Biol
|
2004
|
1.05
|
|
11
|
SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes.
|
Diabetes Care
|
2005
|
1.02
|
|
12
|
Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes.
|
Diabetes Care
|
2006
|
0.91
|
|
13
|
Diabetic vascular disease: it's all the RAGE.
|
Antioxid Redox Signal
|
2005
|
0.85
|
|
14
|
RAGE and its ligands: a lasting memory in diabetic complications?
|
Diab Vasc Dis Res
|
2004
|
0.84
|
|
15
|
New treatments for diabetic neuropathy: pathogenetically oriented treatment.
|
Curr Diab Rep
|
2003
|
0.81
|
|
16
|
Induction of p27KIP1 after unilateral ureteral obstruction is independent of angiotensin II.
|
Kidney Int
|
2002
|
0.80
|
|
17
|
Are advanced glycation end products cardiovascular risk factors in patients with CRF?
|
Am J Kidney Dis
|
2003
|
0.77
|
|
18
|
[AGE-RAGE: a hypothesis or a mechanism?].
|
Herz
|
2004
|
0.75
|